Mawer Damian P C, Eyre David W, Griffiths David, Fawley Warren N, Martin Jessica S H, Quan T Phuong, Peto Timothy E A, Crook Derrick W, Walker A Sarah, Wilcox Mark H
Department of Microbiology, Leeds Teaching Hospitals NHS Trust, UK.
Nuffield Department of Medicine, University of Oxford, UK.
Clin Infect Dis. 2017 May 1;64(9):1163-1170. doi: 10.1093/cid/cix079.
The role of symptomatic patients who are toxigenic strain positive (TS+) but fecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown.
We investigated the contribution of symptomatic TS+/FT- and TS+/FT+ patients in C. difficile transmission in 2 UK regions. From 2-step testing, all glutamate dehydrogenase (GDH)-positive specimens, regardless of fecal toxin result, from Oxford (April 2012 through April 2013) and Leeds (July 2012 through April 2013) microbiology laboratories underwent culture and whole-genome sequencing (WGS), using WGS to identify toxigenic strains. Plausible sources for each TS+/FT+ case, including TS+/FT- and TS+/FT+ patients, were determined using WGS, with and without hospital admission data.
A total of 1447 of 12772 (11%) fecal samples were GDH positive, 866 of 1447 (60%) contained toxigenic C. difficile, and fecal toxin was detected in 511 of 866 (59%), representing 235 Leeds and 191 Oxford TS+/FT+ cases. TS+/FT+ cases were 3 times more likely to be plausibly acquired from a previous TS+/FT+ case than a TS+/FT- patient. Fifty-one of 265 (19%) TS+/FT+ cases diagnosed >3 months into the study were genetically related (≤2 single-nucleotide polymorphisms) to ≥1 previous TS+/FT+ case or TS+/FT- patient: 27 (10%) to only TS+/FT+ cases, 9 (3%) to only TS+/FT- patients, and 15 (6%) to both. Only 10 of 265 (4%) were genetically related to a previous TS+/FT+ or TS+/FT- patient and shared the same ward simultaneously or within 28 days.
Symptomatic TS+/FT- patients were a source of C. difficile transmission, although they accounted for less onward transmission than TS+/FT+ cases. Although transmission from symptomatic patients with either fecal toxin status accounted for a low overall proportion of new cases, both groups should be infection control targets.
产毒菌株阳性(TS+)但粪便毒素阴性(FT-)的有症状患者在艰难梭菌传播中的作用目前尚不清楚。
我们调查了英国两个地区有症状的TS+/FT-和TS+/FT+患者在艰难梭菌传播中的作用。通过两步检测,来自牛津(2012年4月至2013年4月)和利兹(2012年7月至2013年4月)微生物实验室的所有谷氨酸脱氢酶(GDH)阳性标本,无论粪便毒素检测结果如何,均进行培养和全基因组测序(WGS),使用WGS鉴定产毒菌株。利用WGS并结合或不结合住院数据,确定每个TS+/FT+病例(包括TS+/FT-和TS+/FT+患者)可能的感染源。
12772份粪便样本中有1447份(11%)GDH阳性,1447份中有866份(60%)含有产毒艰难梭菌,866份中有511份(59%)检测到粪便毒素,代表235例利兹和191例牛津的TS+/FT+病例。TS+/FT+病例从先前的TS+/FT+病例获得感染的可能性是从TS+/FT-患者获得感染的3倍。在研究进行3个月后诊断的265例TS+/FT+病例中,有51例(19%)与≥1例先前的TS+/FT+病例或TS+/FT-患者存在基因关联(≤2个单核苷酸多态性):27例(10%)仅与TS+/FT+病例有关联,9例(3%)仅与TS+/FT-患者有关联,15例(6%)与两者均有关联。265例中只有10例(4%)与先前的TS+/FT+或TS+/FT-患者存在基因关联,且在同一病房同时或在28天内有过接触。
有症状的TS+/FT-患者是艰难梭菌传播的一个来源,尽管他们导致的后续传播比TS+/FT+病例少。尽管有症状且粪便毒素状态不同的患者传播导致的新病例总体比例较低,但这两组患者都应作为感染控制的目标。